Submissions

Author Guidelines

To download a copy of the complete Scientific Proceedings Author Guidelines, click here.

SUBMISSIONS

All manuscript submissions to the Lung Center of the Philippines Scientific Proceedings shall be through its Open Journal Systems website. A manuscript submission checklist (Form SPLCP-2021-ASC-001) is provided to guide the submission as to the journal’s requirements.

COVER LETTER

A cover letter addressed to the Editor-in-Chief of the Lung Center of the Philippines Scientific Proceedings should be prepared, stating the complete title of the work, list of all authors, and the intention to submit to the Scientific Proceedings. The corresponding author with complete contact information (institutional mailing address, work telephone, fax number [if any], and work e-mail address) should be clearly indicated.
NOTE: Presentation of the study findings as an abstract or poster in previous conferences should be mentioned in the letter, to include information on the title and dates of the conference, as well as awards won, if any.

AUTHOR FORM

The Author Form (SPLCP-2021-AF-001) includes a certification of fulfillment of authorship criteria for all authors listed, declaration of conformity to publication ethics and ethical standards for experiments on human/animal subjects and approval by the appropriate ethics committee, disclosure of potential conflicts of interest where existing, and agreement to copyright transfer. Complete names of the authors, title indicating the highest educational attainment (e.g., MD, MSc, PhD), and name and location of not more than one (1) institutional affiliation, should be indicated.

ETHICAL BOARD APPROVAL (FOR ORIGINAL ARTICLES)

For all original articles, the authors shall submit a scanned copy of the ethical review board approval of the study performed on which the manuscript is based.

INFORMED CONSENT FORM (FOR CASE REPORTS/CASE SERIES)

For case reports, the authors shall submit a scanned copy of the written/informed consent for publication from the involved patient/subject.

For case series whose patient data are reported in aggregate, informed consent is not required. However, if the case series includes patient details that contain individual information which makes them identifiable (e.g., individual case histories, photos, x-rays, etc.), an informed consent form for publication must be submitted.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

All authors are required to individually disclose any potential conflicts of interest using the ICMJE Standard Form for Disclosure of Potential Conflicts of Interest.

MANUSCRIPT

Title Page
The title page should include:

• Complete title of the article which should be informative, concise, meaningful, and as brief as possible (no more than 20 words)
• Name of each author with highest academic degree(s) and complete address of one (1) institutional affiliation
• Listing of any meeting(s)/conference(s) where the material is under consideration for presentation, has been previously presented, and/or has been awarded. Indicate title, place month and year of the meeting/conference.
• Corresponding author’s name, mailing address, telephone, fax, and e-mail address. The corresponding author will be responsible for all questions about the manuscript. Only
  one author is to be designated as corresponding author and he/she does not need to be the first author on the manuscript.
• Appropriate footnotes for explanatory purposes or additional information may be placed with proper cross-referencing to the main text, in the following order of usage: *, **, ***
• Financial support, if any. Provide the agency name and city, company name and city, fellowship name and/or grant number.

Abstract

• Original Articles, Review Articles require a structured abstract of not more than 500 words, with the following four headings:
  • Objective/s: Briefly state the purpose/s or aim/s of the study.
  • Methodology: State the study design (e.g., randomized clinical trial, case-control study, cross-sectional study, systematic review), setting (multi-center, institutional, et cetera), study population. Additional modifiers can be stated (consecutive, retrospective, prospective, observational, interventional, non-consecutive, etc.)
  • Results: Briefly summarize the principal outcome measurements/data obtained. Results should be accompanied by data with confidence intervals and the exact level of statistical significance.
  • Conclusions: Provide brief and concise conclusion(s) directly supported by the data.
  • Keywords• At least 5 keywords listed in the Medical Subject Headings database ([MeSH] of the National Center for Biotechnology Information [NCBI]) should be provided.
• Case Reports or Case Series do not require a structured abstract, with a maximum of 300 words.

Body of the Text

• The manuscript should be written in IMRAD format (Introduction, Methodology, Results and Discussion, Conclusion).
• Organize and prepare the manuscript to include the following sections:
  • Introduction: The Introduction should refer only to the most pertinent past publications and should not be an extensive review of the literature.
    Include a brief background, the research question and/or rationale, objectives/purposes of the study, and major hypothesis to be tested if any.
  • Methodology: Methods should be written with sufficient detail to permit others to duplicate the work.
  • Study Design: State the study design using a phrase such as randomized or nonrandomized clinical trial, case-control study, cross-sectional study, cohort study, case series, case report, systematic review, meta-analysis, review, experimental study, or historical manuscript; Setting: (e.g., multicenter, institutional,
    clinical practice); Participants, Patients, or Study Population: Number of patients, selection procedures, inclusion/exclusion criteria, randomization procedure
    and masking; Intervention or observation procedure(s); Main and secondary outcome measure(s); Data and statistical analyses, to include what software was used
    for the computations. For original articles, statements regarding adherence to the Declaration of Helsinki, approval by the Institutional Review Board (IRB)/Ethics
    Committee, and description of the informed consent process should be included.
  • Results: Results must be concise. Provide demographic data of the study population. Describe outcomes and measurements in an objective sequence with
    minimum discussion. Data should be accompanied by confidence intervals (usually at the 95% interval) and exact p-values or other indications of statistical significance.
  • Discussion: The discussion should be restricted to the significant findings presented. Avoid excessive generalization and undue speculation. Elucidate on (but do not reiterate) the results, provide responses to other and contradictory literature, identify limitations or qualifications of the study, and state the conclusions that are directly supported by the data. Give equal emphasis to positive and negative findings, whether and what additional study is required, and conclude with the clinical applications or implications supported by the study.
  • Conclusion/s: The conclusion(s) should be directly supported by the results. Authors should avoid making statements on economic benefits and costs unless the manuscript includes economic data and analyses.
  • References: Cite only published studies as references. Quote from the entire study, not the abstract. Authors may acknowledge “unpublished data” or submitted articles within parentheses in the text. Reference to a “personal communication” within parentheses in the text must be accompanied by a signed permission letter from the individual being cited.

Abbreviations

• Restrict abbreviations to those that are widely used and understood. Avoid abbreviations that have meaning only in the context of your specific manuscript.
• All abbreviations should be spelled out once (the first time they are mentioned in the text) followed by the abbreviation enclosed in parentheses.

Measurements

• All measurements and weights should be expressed in SI units.

Drugs, Instruments, Equipment

• Use generic names only in the text body. State the trade name of a particular drug cited in parentheses including manufacturer’s name, city, state and/or country when first mentioned in the text. With regard to instruments or equipment utilized in the study, enclose in parentheses the specific model, manufacturer’s name, city, state and/or country.

Conflicts of Interest

• There should be a statement disclosing conflicts of interest where existing, source of funding for the study and manuscript, and acknowledgements to individuals/ groups of persons, or institution/s.

Funding Sources

• Funding source/s for the study on which the manuscript is based, to include the writing of the manuscript, should be stated.

Acknowledgments

• Contributors to the work who do not fulfill the authorship criteria should be acknowledged.

Tables, Figures, Illustrations and Photographs
Tables

• Each table must be titled and numbered consecutively using Arabic numbers as mentioned in the text. The title should be brief and fully understandable without reference to the text. Each table column and row must have a heading. Tables that indicate the mean should have
  the corresponding standard deviation. Legends must identify all symbols that appear on the tables and graphs. A maximum of five (5) tables may be included in the manuscript.

Figures (Graphs, Illustrations, and Photographs)

• Each final figure should be submitted as individual Joint Photographic Experts Group (JPEG), Portable Network Graphics (PNG), or Tag Image File Format (TIFF) files with appropriate labels (figure number, title).
• Submit the original, raw, and unedited files in the abovementioned formats with corresponding labels that shall allow comparison with the final figures.
• Disclose if there are modifications, such as cropping, changes in color, orientation, or placement of arrows or shapes.
• Photographs (clinical photographs, fluorescein angiograms, computed tomography [CT] scans, magnetic resonance imaging [MRI], X-ray, photomicrographs, transmission/scanning electron micrographs [TEM/SEM], graphs, etc. should have a resolution of at least
  600 dpi.
• Graphs may be submitted in “Power Point” or “Excel” format. Text in figures must not be smaller than 10 points when finally reproduced in the Journal.
• Illustrations must be professionally rendered with appropriate labels.
• Raw data may be requested by the Editorial Board for verification of computations.
• Each figure must be numbered consecutively in Arabic numerals by order of citation in the text. Each should have a brief explanatory legend. Legends must identify all symbols or letters that appear on the prints. Histologic figures, stains, and magnifications should be noted in the legend. Graphs that indicate the mean should include the standard deviation.
• Clinical photographs should be masked when possible to prevent identification of the patient (e.g. placement of a censor bar over the eyes).
• Photographs may be in black and white, or submitted in full color.
• NOTE: Any figure that has been published elsewhere or adapted should have an acknowledgement to the original source. A copy of the release to publish the figure signed by the copyright holder must also be submitted.
• Up to a maximum of five (5) items only per type may be included.

Appendix

• Appendices should be used very sparingly. However, it is appropriate to provide survey forms, to list the members of a study group, or explain complex formulas or information. In studies involving a study group, the writing group authors should be listed along with the group name on the title page. Other group members should be listed in an appendix.

References

• List only references that are pertinent to the manuscript.
• References should be numbered consecutively in the text and in the reference list. In the text, reference numbers are entered as superscripts. The references must be verified by the author(s) against the original documents. PubMed offers a useful reference checker. (http://www.ncbi.nlm.nih.gov)
• References to journal articles should include: the author or authors (for more than four authors, list only the first three followed by “et al.”), title, journal name, (as abbreviated
  in Index Medicus), year, volume number, and inclusive page numbers.
• References to books should include: the author or authors, chapter title (if any), editor or editors (if any), book title, edition (other than the first), city of publication, publisher copyright year, and inclusive pages of the chapter or section cited.
• Website references must include author (or website owner), title of article, date article was posted, publication (if applicable), complete website address and date accessed.

Examples:

• Journal Article (if four or fewer authors, list all)
  • Miller WT, Macgregor RR. Tuberculosis: Frequency of unusual radiographic findings. Am I of Roentgenology 1978; 130: 867-75.
• Journal Article (if five or more authors, list only the first three and add et al.)
  • Libshitz HI, Mckenna RJ, Haynie TP, et al. Mediastinal evaluation in lung cancer. Radiology 1984; 151:295-99.
• Chapter in Book
  • Meltzer PS, Kallioniemi A, Trent JM, Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New
    York: McGraw-Hill; 2002. p. 93-113.
• Book
  • Murray, PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
  • Gilstrap LC 3rd, Cunningham FG, VanDorsten JP, editors. Operative obstetrics. 2nd ed. New York: McGraw-Hill; 2002.
• Website
  • World Health Organization. Hospital infection control guidelines for severe acute respiratory syndrome. April 16, 2003: http://who.int/csr/sars/infectioncontrol/en (accessed April 24, 2003).

NOTE: For a complete sample of references, please refer to: http://www.nilm.gov/bsd/uniform_requirements.html